MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polcythemia Vera
Condition: Polycythemia Vera Interventions: Drug: Ruxolitinib; Drug: Hydroxycarbamide; Drug: Interferon-Alpha Sponsors: University of Birmingham; Novartis; MPN Voice; National Cancer Institute, France Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials